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Abstract 
Background: Data regarding the influences of gender in metabolic syndrome (MetS) among patients using antiret-
roviral treatment (ART) in Ethiopia is scarce. The aim of this study was to assess the influences of gender in MetS and 
its components among HIV-infected patients receiving ART.
Methods: A cross-sectional study was conducted between February 2012 and April 2013. Data on demographic, 
clinical and anthropometric characteristics were collected from 185 HIV patients using ART. Glucose and lipid profiles 
were measured from overnight fast blood. The International Diabetes Federation (IDF) and United States national 
cholesterol education program: adult treatment (US NCEP-ATP) panel III criteria were used to define MetS.
Result: A total number of 185 (36.8 % males and 63.2 % females) participants were recruited in this study. The 
overall prevalence of MetS was 24.3 and 17.8 %, diagnosed using IDF and NCEP-ATP criteria respectively. Using IDF 
criteria, MetS was significantly higher in females compared to males (33.3 vs. 8.8 %; p = <0.0001) respectively. Low 
HDL-c and central obesity were significantly higher MetS components in female compared to males (p = 0.003); and 
(p = <0.0001, using IDF and NCEP-ATP criteria) respectively. BMI >25 kg/m2 was significantly associated with MetS in 
both IDF and NCEP-ATP criteria: unadjusted (UOR) and adjusted odds ratio (AOR) with 95 % CI were 3.0 (1.3–6.5) and 
3.8 (1.5–9.8); as well as 3.2 (1.4–7.4) and 3.4 (1.4–7.4) respectively. Furthermore age >40 years was significantly associ-
ated with MetS using NCEP-ATP: UOR and AOR (95 % CI) were 3.1 (1.2–8.3), and 3.8 (1–13.70) respectively.
Conclusion: Comprehensive medical care approach including with MetS components are a crucial instruments in 
order to minimize the risk of developing cardiovascular diseases in HIV-infected patients using ART.
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Background
Metabolic syndrome (MetS) is one of highly preva-
lent disease, a global challenge at the moment and it has 
been playing a major role as a marker for metabolic dis-
orders [1, 2]. According to United States National Cho-
lesterol Education Program/Adult Treatment Panel III 
(US  NCEP ATP-III) criteria, MetS is defined by three 
or more of the following features: abdominal obesity, 
hypertriglyceridemia, low levels of high density lipoprotein 
cholesterol (HDL-c), insulin resistance, and hypertension 
[3]. The characteristics of MetS have been reported to dif-
fer between HIV infected patients and the general popula-
tion, and these differences could be attributed to HIV and/
or its associated therapies. The most commonly achieved 
metabolic criteria for MetS in HIV infected patients were 
hypertriglyceridemia and low HDL-C, while the least com-
mon criterion was increased waist circumference (WC) 
[4]. Also this disorder confers the risk of developing non-
communicable diseases such as cardiovascular diseases 
and diabetes mellitus among individuals living with HIV 
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infections and being on anti-retroviral treatments (ART) 
[5]. MetS was commonly and rapidly observed in sub 
Saharan patients initiating combined ART [6] and also the 
reports showed that it is more common in women than 
men [7, 8]. In contrast one study revealed that absence 
differences in the prevalence of MetS between men and 
women when stratified by race [9]. MetS diagnosis can be 
crucial for decision-making in health care regarding car-
diovascular disease prevention and patient management. 
However, data of MetS in HIV-infected subjects in com-
parison to gender in Ethiopia is scarce.
Therefore the aim of this study was to assess gender 
influences in the pre-valence of MetS and its components 
among HIV-infected patients using first line ART.
Methods
Study setting and study population
A hospital based prospective cross-sectional study was 
conducted at the ART clinic of Hawassa University Refer-
ral Hospital between February 1, 2013 and April 30, 
2013. Hawassa University Referral Hospital is located in 
Hawassa town, which is the capital city of the southern 
nations, nationalities and peoples’ region (SNNPR). It is 
one of the hospitals which provide ART services in the 
region. During the study period, there were 4504 adult 
HIV-positive clients in  the ART clinic (1796 males and 
2708 females). Of whom 2354 were on ART while the 
remaining 2156 clients were ART naives. Participants 
used first-line ART regimens that included nucleoside 
reverse transcriptase inhibitors (NRTIs): lamivudine 
(3TC), Zidovudine (ZDV), or Stavudine (d4T) or Teno-
fovir disoproxil fumarate (TDF) with one of non-nucle-
oside reverse transcriptase inhibitors (NNRTIs): either 
NVP or EFV. Patients who had had their therapy regi-
mens changed during follow-up were excluded. All par-
ticipants included were having age ≥18 years and have a 
good ART adherence (adherence rate ≥95 %).
Sample size and sampling technique
The sample size was calculated based on single popula-
tion proportion formula using a confidence interval (CI) 
of 95 % and a 13 % prior prevalence of MetS among HIV 
infected patients receiving ART from Benin [6].
where, n = sample size, p = proportion of MetS patients 
who may have MetS and d  =  assumed marginal error. 
Based on the above formula and with including 6  % 
non response rates, the sample size was calculated to be 
185. To select participants from the study population, 
daily patient flow was assessed from the data log at the 
data clerk office of the ART clinic and patient flow was 
n = (Zα/2)
2p (1− p)/d2
assessed for a week. Finally the trend showed that the 
average daily patient flow was approximately 27 cases for 
ART treated patients. Participants receiving lipid altering 
therapies, women with pregnancy, known diabetes mel-
litus patients and renal failures were not included in the 
study.
Assessments and measurements
Structured questionnaires were used to collect data on 
the socio-demographic, clinical and anthropometrics 
information. Following this, trained ART nurse recorded 
physical/anthropometric examinations. Blood pressure 
(BP) was measured by ART clinic nurses using a stand-
ard adult arm cuff of mercury type sphygmomanometer 
after a minimum of 5  min rest of patients in the clinic. 
Three BP measurements were taken to maintain accuracy 
and the mean of the three readings was calculated and 
WC was taken at the midpoint between the lower margin 
of the last palpable rib and the top of the iliac crest (hip 
bone). EDTA anticoagulated blood sample was used for 
measuring of patient’s current CD4+ lymphocyte count 
by using flow-cytometry instrument (Becton–Dickinson, 
CA, USA). Blood sample was collected from each partici-
pant after 8–12 h overnight fast and centrifuged at 3000 
cycles/min for 5–10 min, and then serum was obtained 
for lipid profiles. Furthermore, serum samples were 
analyzed for fasting glucose level and lipid profile [total 
cholesterol (TC), HDL-c, LDL-c and TGs] using A25 ran-
dom access analyzer (BioSystems™, Spain). TC/HDL-c 
ratio was calculated and enzymatic colorimetric assay 
method was used for the measurement of TC (CHOD-
PAP method) and TGs (GPO-PAP method) while HDL-c 
and LDL-c measurements were done by utilizing direct 
homogeneous enzymatic colorimetric assay technique. 
Glucose level was measured by the glucose oxidase 
method (GOD-PAP). All the reagents, used for the glu-
cose and lipid profile testing, were from Human Gesells-
chaft fu¨r Biochemica und Diagnostica mBH (Germany).
Definition of metabolic syndrome
MetS defined according to International Diabetes Fed-
eration (IDF), participants had at least three of the fol-
lowing risk factors: abdominal obesity (defined as WC 
adjusted for Africans is: ≥94 cm for men and ≥80 cm for 
femeles); raised TG level (≥150 mg/dl); reduced HDL-c 
(<40  mg/dl in males and <50  mg/dl in females); raised 
BP (systolic BP ≥ 130 or diastolic BP ≥ 85 mmHg); and 
raised FBG (≥100  mg/dl) [10]. Whereas according to 
US NCEP-ATP III definition, abdominal obesity (defined 
as WC > 102 cm in males and >88 cm in females); raised 
FBG (≥110  mg/dl) but abnormal lipid profiles and BP 
levels were alike to IDF criteria [11].
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Statistical analysis
Statistical analysis was done using Statistical Package 
for Social Sciences (SPSS) Version 20. Categorical vari-
ables were summarized as frequencies and percentages, 
continuous variables were tabulated via mean values and 
standard deviation while Median values and interquar-
tile range (IQR) were tabulated for skewed variables. Chi 
square test and fisher exact test were used for categorical 
variables while comparison of quantitative variables were 
done by student t test or Mann–Whitney U test for those 
parameters did not follow normal distribution. Univari-
ate and multivariate binary logistic regression analysis 
was used to assess the differences in the distribution of 
categorical variables for study groups. p < 0.2 was used as 
a cutoff to include variables for multivariate binary logis-
tic regression model. Finally p < 0.05 at 95 % confidence 
intervals (CI) was considered as statistically significant.
Data quality control
Trained nurses working in the ART follow up clinic were 
concerned in the collection of socio-demographic, clini-
cal and physical/anthropometric characteristics from the 
patients. Quality control samples were run before run-
ning patient samples and along with patient samples in 
order to check the correct functioning of instruments, 
laboratory reagents, and technical performances. All lab-
oratory performances were done by lab technologists and 
using standard operating procedures (SOPs) from sample 
collection to result releasing.
Ethical consideration
The study was approved by the Institutional Review 
Board of the College of Medicine and Health Sciences, 
Hawassa University. Participation was entirely voluntary, 
and written consent was obtained from the study par-
ticipants. Any information obtained during the study was 
kept with utmost confidentiality. All laboratory analysis 
was performed free of charge, and the results were pro-
vided to the clinicians for possible management.
Results
Socio‑demographic, clinical and treatment characteristics 
of study participants
A total number of 185 [68 (36.8 %) males and 117 (63.2 %) 
females] with a median [interquartile range (IQR)] age 
of 32 (26.5–38) years, participated in the study. Majority, 
54.6, 58.4, and 50.2 percent of the study participants were 
married, private employed and WHO clinical stage ≥  III 
respectively. The 22.7, 12.4, and  44.3 percent  of HIV 
patients were drink alcohol (rarely to regularly), had his-
tory of cigarette smoking and had sedentary life style 
respectively. Males were significantly higher in cigarette 
smoking compared to females (23.5 vs. 6.0 %; p = <0.0001) 
respectively. Mean [±standard deviation (SD)] of body 
weight and median (IQR) of CD4+ count were 59.9 (11), 
and 418 (282-418) respectively. In addition males had 
significantly higher mean body weight and lower median 
CD4+ count when compared with females (65 vs. 57; 
p = <0.0001 and 383 vs. 473; p = 0.005) respectively.
First-line HAART regimens were combinations of 
2NRTI and 1NNRTI. All regimens included 3TC. The 
mean of treatment duration was 43.7  months (range: 
6–96 months). The proportion of patients on ZDV/3TC/
EFV, and ZDV/3TC/NVP regimens were 35 (18.9  %) 
and 38 (20.5  %) respectively, while those on d4T/3TC/
EFV, and d4T/3TC/NVP regimens were 27 (14.6 %) and 
26 (14.1 %) respectively. Those on TDF/3TC/EFV based 
regimen account for 47 (25.4  %), while the remaining 
12 (6.5  %) were on TDF/3TC/NVP. Accordingly, 39.4  % 
patients were on ZDV; 31.9 % were on TDF; 28.6 % were 
on d4T; 58.9 % patients were on EFV, and 41.1 % were on 
NVP (Table 1).
The prevalence of MetS and its components
Mean (±SD) of systolic BP, diastolic BP, and WC of 
the individuals were 112 (15.7), 72.7 (10) and 85.4 
(9.7) respectively. The mean HDL-c was significantly 
lower in male when compared to females (42.1 vs. 51.1; 
p = <0.0001). However mean TGs, and WC were signifi-
cantly higher in male compared to females (196 vs. 156; 
p = 0.005, and 87.7 vs. 85; p = 0.01) respectively. In addi-
tion the mean TC/HDL-c ratio and FBG also showed sig-
nificantly high trend in males (Table 2).
The prevalence of low HDL-c was significantly higher 
in males compared to females. In contrast TG ≥ 150 mg/
dl was significantly higher in males compared to females. 
The abnormal WC was significantly higher in female 
when compared to males (32.5 vs. 5.9  %; p  =  <0.0001 
diagnosed using NCEP-ATP and 70.1 vs. 19.1  %; 
p =  <0.0001 using IDF) respectively. The proportion of 
MetS was assessed by using two definitions. Accord-
ing to the IDF criteria, the overall prevalence of MetS 
was 24.3  % (45/185), females have significantly higher 
rate of MetS, 33.3 % (39/117), when compared to males, 
8.8 % (6/68); p = <0.0001. Whereas MetS was 17.8 % in 
NCEP-ATP criteria, and it was not significantly different 
between sex (females 17.9 % vs. males 17.6 %; p = 0.95). 
Based on the IDF criteria 58 (31.3 %) patients had FBG 
level >100 mg/dl and significantly higher in males com-
pared to females (42.6 vs. 24.8 %; p = 0.01) (Table 3).
Factors associated with prevalence of metabolic syndrome
Univariate and multivariate analysis models were also 
applied to assess independent risk factors for MetS. In 
both models, BMI > 25 kg/m2 was significantly associated 
with MetS in IDF as well as NCEP-ATP III criteria, while 
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Table 1 Characteristics of HIV infected patients using ART 
with gender category at Hawassa, Southern Ethiopia
Values are the number (percent) for variables unless otherwise indicated
WHO world health organization, NRTI nucleoside reverse transcriptase inhibitor, 
NNRTI non nucleoside reverse transcriptase inhibitor, BMI body mass index, 






Age (years), median (IQR) 35 (28.2–40.0) 30 (25–35)
 <25 8 (11.8) 32 (27.4)
 26–35 27 (39.7) 61 (52.1)
 36–45 26 (38.2) 21 (17.9)
 ≥46 7 (10.3) 3 (2.6)
Marital status
 Single  15 (22.0) 24 (20.5)
 Married 38 (55.9) 54 (46.1)
 Divorced 7 (10.3) 12 (10.2)
 Widowed 8 (11.7) 27 (23.1)
Work status
 Unemployed 6 (8.8) 14 (11.9)
 Government 16 (23.5) 14 (11.9)
 Private 43 (63.2) 53 (25.6)
 Student 3 (4.4) 6 (5.1)
 A housewife – 30 (29.0)
Physical exercise
 Sedentary 25 (36.7) 57 (48.7)
 Moderate 38 (55.9) 59 (50.4)
 Vigorous 5 (7.3) 1 (0.8)
BMI (kg/m2) 22.2 (3.2) 22.2 (3.7)
 <18.5 4 (5.9) 21 (17.9)
 18.5–24.9 50 (73.5) 75 (64.1)
 ≥25 14 (20.6) 21 (17.9)
CD4, cells/µl, median (IQR) 340 (200–486) 433 (326–572)
 <200 14 (20.6) 10 (8.5)
 200–400 25 (36.7) 32 (27.4)
 ≥400 29 (42.7) 75 (64.1)
WHO clinical stage
 I 21 (30.9) 37 (31.6)
 II 13 (19.1) 21 (17.9)
 III 29 (42.6) 48 (41.0)
 IV 5 (7.3) 11 (9.4)
NRTIs
 AZT 21 (30.9) 52 (44.4)
 TDF 27 (39.7) 32 (27.3)
 d4T 20 (29.4) 33 (28.2)
NNRTIs
 EFV 46 (67.6) 63 (53.8)
 NVP 22 (32.3) 54 (46.1)
 ART duration (months) 41.4 (19.4) 45.1 (21.5)
Table 2 Gender based prevalence of  parameters in  HIV 
infected patients using ART at Hawassa, Southern Ethiopia
Values are the Mean ± SD for continuous variables unless and otherwise 
indicated
SBP systolic blood pressure, DBP diastolic blood pressure, TC total cholesterol, 
HDL-c high-density lipoprotein cholesterol, LDL-c low- density lipoprotein 
cholesterol, TG triglyceride, FBG fast blood glucose, SD standard deviation, WC 
waist circumference
Parameters Males Females p value
n = 68 n = 117
Total cholesterol 188 (49.4) 201 (50.2) 0.19
 <200 mg/dl, n (%) 43 (63.2) 64 (54.7)
 ≥200 mg/dl 25 (36.8) 53 (45.3) 0.26
HDL-cholesterol 42.1 (10.3) 51.1 (31.9) <0.0001
LDL-cholesterol 108 (37.7) 115 (42.4) 0.47
 <130 mg/dl, n (%) 46 (67.6) 82 (70.0)
 ≥130 mg/dl, n (%) 22 (32.3) 35 (30.0) 0.47
Triglycerides 196 (104.2) 156 (98.5) 0.005
FBG 98.6 (15) 92.7 (17) 0.006
TC/HDL-c ratio 4.6 (1.3) 4.3 (1.2) 0.03
 <5, n (%) 42 (61.7) 93 (79.5)
 ≥5, n (%) 26 (38.2) 24 (20.5) 0.009
WC 87.7 (10) 84 (9) 0.01
SBP 113.1 (14.2) 111.3 (16.5) 0.44
DBP 73.9 (9.7) 71.9 (10.1) 0.20
Table 3 Pattern of  MetS and  its components in  gender 







SBP ≥130 mmHg 9 (13.2) 13 (11.1) 0.66
DBP >85 mmHg 7 (10.3) 15 (12.8) 0.63
FBG (NCEP-ATP criteria) ≥110 mg/
dl
14 (20.6) 13 (11.1) 0.07
FBG (IDF criteria) ≥100 mg/dl 29 (42.6) 29 (24.8) 0.01
Hypertensive (≥130/85 mmHg) 7 (10.3) 11 (9.4) 0.84
TG ≥150 mg/dl 39 (57.3) 44 (37.6) 0.009
Low HDL-c (<40 mg/dl in males and 
<50 in females)
39 (57.3) 91 (77.8) 0.003
WC (IDF criteria) ≥94 cm in males 
and ≥80 cm in females
13 (19.1) 82 (70.1) <0.0001
WC (NCEP criteria) ≥102 cm in males 
and ≥88 cm in females
4 (5.9) 38 (32.5) <0.0001
MetS (IDF criteria) 6 (8.8) 39 (33.3) <0.0001
MetS (NCEP-ATP criteria) 12 (17.6) 21 (17.9) 0.95
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being female was significantly associated with MetS in 
IDF criteria only. Furthermore in NCEP-ATP III criteria, 
age over 40 years was significantly associated with MetS 
(Table 4).
Discussion
The aim of this cross sectional study was to assess the 
pre-valence of MetS and its components in gender among 
HIV-infected patients using first line ART in a resource 
limited setting. The MetS is a complex disturbance rep-
resented for a whole of cardiovascular risk factors, usu-
ally associated to the central adiposity, dyslipidaemia and 
insulin resistance.
The overall prevalence of MetS in the study is 24.3  % 
in IDF where as 17.8  % in NCEP-ATP criteria. In com-
parable with this finding, a number of international 
studies point out prevalence’s ranging from 7.4 % to 27 % 
[12–15]. Conversely high rate of MetS than the present 
study  was reported by Diehl et  al. [16] from Londrina, 
PR (36 %) and Troian et al. from Santa Maria, RS (38.2 %) 
[17]. Also the report of Benin indicated lower rate (13 %) 
of MetS compared to our finding [6]. This indicates meta-
bolic complications of HIV infected patients using ART 
bring in them to future risk of cardiovascular diseases 
and diabetes, despite improvement of mortality and mor-
bidity conferred by immune reconstitution [18]. Females 
had significantly higher MetS (33.3 %) compared to males 
(8.8  %) in IDF criteria. Similarly the studies reported 
from Latin America and Miami showed that females had 
significantly high prevalence of MetS compared to males 
[19, 20]. In addition, this study indicated that female sex 
was significantly associated risk factor for developing 
Table 4 Association of  independent factors with  metabolic syndrome among  HIV infected patients using ART 
at Hawassa, southern Ethiopia
ART antiretroviral therapy, COR crude odds ratio, AOR adjusted odds ratio, CI confidence interval, BMI body mass index, EFV Efavirenz, NVP Nevirapine, NNRTI non 
nucleoside reverse transcriptase inhibitors
Explanatory  
variable














 ≤25 30 (16.2) 1.00 1.00 21 (11.3) 1.00 1.00
 >25 15 (8.1) 3.0 (1.3–6.5) 3.8 (1.5–9.8) 12 (6.5) 3.2 (1.4–7.4) 3.4 (1.3–9.2)
 p value 0.006 0.005 0.006 0.01
Gender
 Male 6 (3.2) 1.00 1.00 12 (6.5) 1.00 1.00
 Female 39 (21.1) 5.1 (2.0–12.9) 7.9 (2.6–24.1) 21 (11.3) 1.0 (0.47–2.3) 1.5 (0.24–1.8)
 p value <0.0001 <0.0001 0.19 0.43
Age (years)
 ≤40 41 (22.1) 1.00 1.00 25 (13.5) 1.00 1.00
 >40 4 (2.1) 0.66 (0.21–2.0) 2.0 (0.45–9.5) 8 (4.3) 3.1 (1.2–8.3) 3.8 (1.0–13.7)
 p value 0.21 0.35 0.02 0.04
ART use (months)
 ≤48 22 (11.9) 1.00 1.00 20 (10.8) 1.00 1.00
 >48 23 (12.4) 1.8 (0.95–3.7) 2.3 (1.0–5.4) 13 (7.0) 0.99 (0.46–2.1) 0.8 (0.32–1.9)
 p value 0.07 0.04 0.20 0.33
Cigarette
 Never smoke 43 (23.2) 1.00 1.00 28 (15.1) 1.00 1.00
 Still smoking 2 (1.1) 0.26 (0.06–1.1) 0.17 (0.03–1.0) 5 (2.7) 1.3 (0.45–3.9) 0.47 (0.10–2.1)
 p value 0.08 0.05 0.18 0.33
Education
 Illiterate 1 (0.5) 1.00 1.00 3 (1.6) 1.00 1.00
Primary 22 (11.9) 6.7 (0.8–53.3) 10.1 (1.1–94) 15 (8.1) 1.2 (0.31–4.7) 0.85 (0.17–4.3)
 p value 0.07 0.04 0.16 0.24
Secondary and above 22 (11.9) 6.2 (0.79–49.9) 10.9 (1.1–104) 15 (8.1) 1.1 (0.3–4.4) 1.1 (0.45–2.8)
 p value 0.08 0.04 0.21 0.37
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MetS and this in line with the other studies report [21, 
22]; in contrast, one study revealed that gender has no 
significant association with MetS [23]. Among the com-
ponents of MetS, the  abnormal WC was significantly 
higher in females when compared to males. Similarly the 
study report from Cameroon indicated that the depicted 
parameter was significantly higher in females [24]. The 
present study indicate males have significantly raised 
TG compared to females, however the study report 
from Cameroon showed that raised TG was higher in 
females [24]. The central obesity was significantly higher 
in females when compared to males in both criteria and 
it is comparable with the studies report from Brazil [25], 
and Miami [20]. In addition the Proportion of raised TC/
HDL-c ratio was significantly higher in males when com-
pared to females and it indicates a potential risk for HIV-
infected patients to develop cardiovascular diseases in a 
significant proportion in the near future [11, 26–28].
The proportion of reduced HDL-c was significantly 
higher in females (77.8  %) when compared to males 
(57.3  %). Comparably the study report from other part 
Ethiopia showed that females had higher proportion 
(53.4  %) compared to males (36.7  %); however the rate 
was lower than the present study [29].
Abnormal BMI was significantly associated with MetS 
in IDF as well as NCEP-ATP criteria, and likewise several 
studies report illustrated that the BMI is a quantitative 
predictor of MetS [30–32]. Furthermore the level of edu-
cation was directly associated with MetS. Similar findings 
have also been reported in urban India where the preva-
lence of MetS was significantly higher among study par-
ticipants with level of education [33, 34], and Alencastro 
et al. reported that education to be an independent pre-
dictor of MetS [35].
Limitations of the study
We didn’t do the nutritional assessment due to its dif-
ficulty; however the increased risk of cardiovascular 
diseases associated with described MetS and its com-
ponents is well known. The other limitations were the 
cross-sectional nature of the study, small number of male 
participants, and lack of HIV negative controls. In addi-
tion long term use of ART may have an impact on cardio-
vascular system.
Conclusion
MetS was detected in 24.3 and 17.8 % in IDF and NCEP-
ATP III criteria respectively. According to IDF criteria, 
the prevalence of MetS was significantly higher compared 
to males. In both criteria central obesity was significantly 
higher in females when compared to males. Also MetS 
components like raised TG was significantly higher in 
males, where as reduced HDL-c was significantly higher 
in females. Raised BMI was significantly associated risk 
factor of MetS in both criteria and female sex was signifi-
cantly associated with MetS in IDF criteria only. Further-
more age more than 40 year was significantly associated 
with MetS in NCEP-ATP criteria.
MetS among patients on ART for a longer duration 
may put them at high risk of cardiovascular diseases. 
Therefore, screening for fasting blood glucose and lipid 
profiles should be done before ART initiation and peri-
odically through treatment. Beside physicians/clini-
cians should be aware of the magnitude of the problem, 
and ought to include into daily practice interventions to 
decrease MetS for those patients. Also advising patients 
for regular exercise and treat with lipid lowering agents 
for patients with deranged lipid profiles. Furthermore we 
put forward long term controlled cohort study to evalu-
ate gender and treatment duration influence on MetS 
among patients on antiretroviral treatment including 
with nutritional strata.
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